Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GABRINOX: GemBrax followed by Folfirinox in Metastatic Pancreatic Adenocarcinoma
NCT01964287Phase 2Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Sep 2013
- Primary completion
- Dec 2016
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of nab-paclitaxel, gemcitabine, oxaliplatin, irinotecan, fluorouracil in pancreatic adenocarcinoma (PDAC), sponsored by Institut du Cancer de Montpellier. Started Sep 2013; status: completed.
02
Drugs
nab-paclitaxelgemcitabineoxaliplatinirinotecanfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01964287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01964287.